Abstract
Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-10 |
| Number of pages | 10 |
| Journal | AIDS and Behavior |
| DOIs | |
| State | Accepted/In press - Dec 30 2017 |
Fingerprint
Keywords
- HIV
- Long-acting injectable
- Men
- PrEP
- Providers
- Qualitative
- Risk behavior
ASJC Scopus subject areas
- Social Psychology
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Cite this
Expanding the Menu of HIV Prevention Options : A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. / Kerrigan, Deanna; Mantsios, Andrea; Grant, R.; Markowitz, M.; Defechereux, P.; la Mar, M.; Beckham, Sarah; Hammond, P.; Margolis, D.; Murray, M.
In: AIDS and Behavior, 30.12.2017, p. 1-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expanding the Menu of HIV Prevention Options
T2 - A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States
AU - Kerrigan, Deanna
AU - Mantsios, Andrea
AU - Grant, R.
AU - Markowitz, M.
AU - Defechereux, P.
AU - la Mar, M.
AU - Beckham, Sarah
AU - Hammond, P.
AU - Margolis, D.
AU - Murray, M.
PY - 2017/12/30
Y1 - 2017/12/30
N2 - Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.
AB - Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.
KW - HIV
KW - Long-acting injectable
KW - Men
KW - PrEP
KW - Providers
KW - Qualitative
KW - Risk behavior
UR - http://www.scopus.com/inward/record.url?scp=85039736006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039736006&partnerID=8YFLogxK
U2 - 10.1007/s10461-017-2017-x
DO - 10.1007/s10461-017-2017-x
M3 - Article
C2 - 29290075
AN - SCOPUS:85039736006
SP - 1
EP - 10
JO - AIDS and Behavior
JF - AIDS and Behavior
SN - 1090-7165
ER -